Author

admin

Browsing

About Earthwise Minerals

Earthwise Minerals Corp. (CSE: WISE; FSE: 966) is a Canadian junior exploration company focused on advancing the Iron Range Gold Project in southeastern British Columbia near Creston, B.C. The Company holds an option to earn up to an 80% interest in the fully permitted project, which is road-accessible and situated within a prolific mineralized corridor. The property covers a 10 km x 32 km area along the Iron Range Fault System and hosts multiple high-grade gold showings and large-scale geophysical and geochemical anomalies.

For more information, visit www.earthwiseminerals.com.

EARTHWISE MINERALS CORP.,

ON BEHALF OF THE BOARD

‘Mark Luchinski’

Contact Information:

Mark Luchinski
Chief Executive Officer, Director
Telephone: (604) 506-6201
Email: luch@luchccorp.com

Forward Looking Statements

This news release includes statements that constitute ‘forward-looking information’ as defined under Canadian securities laws (‘forward-looking statements’) including, without limitation, statements respecting the Offering and the intended use of proceeds therefrom. Statements regarding future plans and objectives of the Company are forward looking statements that involve various degrees of risk. Forward-looking statements reflect management’s current views with respect to possible future events and conditions and, by their nature, are subject to known and unknown risks and uncertainties, both general and specific to the Company. Although the Company believes the expectations expressed in its forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and actual outcomes may differ materially from those in forward-looking statements. Additional information regarding the various risks and uncertainties facing the Company are described in greater detail in the ‘Risk Factors’ section of the Company’s annual management’s discussion and analysis and other continuous disclosure documents filed with the Canadian securities regulatory authorities which are available at www.sedarplus.ca. The Company undertakes no obligation to update forward-looking information except as required by applicable law. The reader is cautioned not to place undue reliance on forward-looking statements.

For more information, please contact Mark Luchinski, Chief Executive Officer and Director, at luch@luchccorp.com or (604) 506-6201.

Source

This post appeared first on investingnews.com

Statistics Canada released its second-quarter gross domestic product (GDP) figures on Friday (August 29). The data showed that the Canadian economy shrank 0.4 percent in the second quarter and declined 1.6 percent on an annualized basis. The decrease comes following first-quarter gains of 0.5 percent and a 2 percent annualized increase.

Much of the decrease was attributed to a 7.5 percent drop in exports compared to Q1. Canadian exports had risen 1.4 percent in the first three months of the year as US companies increased imports to get ahead of incoming tariffs.Excluding the lower costs at the pumps, CPI remained steady at 2.5 percent, the same increase as May and June.

On an industry level, new monthly data for June shows that the resource sector grew by 0.1 percent after two months of declines, primarily driven by a 2.6 percent gain in the oil and gas subsector, with oil sands extraction rising 6.4 percent over May. However, gains were offset by a 9.7 percent monthly decline in support activities for the resource sector, its largest drop in five years, led by reduced rigging and drilling activities.

South of the border, the US Bureau of Economic Analysis released its second estimate for Q2 real GDP on Thursday (August 28). The data shows that US GDP grew by 3.3 percent during the quarter, 0.3 percent higher than its advance estimate.

According to the agency, the figure reflects a decrease in imports and an increase in consumer spending. The GDP’s upward momentum was tempered by a 13.8 percent decrease in private domestic investment, marking the most significant decline since 2020, during the pandemic.

The growth follows a 0.5 percent decrease in the first quarter of 2025, which saw a significant rise in imports.

This week also saw US President Donald Trump attempt to remove US Federal Reserve Board of Governors member Lisa Cook. Trump justified the decision based on Federal Housing Finance Agency Director Bill Pulte’s claim that Cook claimed primary residence in two mortgage applications submitted weeks apart in 2021. She was confirmed to the Fed Board of Governors in May 2022.

Cook is fighting the move in court, with her lawyer stating that Trump’s unsubstantiated allegation of an event prior to Cook’s confirmation does not meet the ’cause’ required by the Federal Reserve Act to remove a governor. By the end of the day on Friday, the judge hearing the case did not reach a decision on whether to issue a temporary restraining order that would allow Cook to remain in her role during the case.

Pulte has previously made similar allegations against other prominent Democrats, including California Senator Adam Schiff, a vocal critic of Trump, and New York Attorney General Letitia James, who oversaw a civil suit against Trump that resulted in a US$500 million award.

Trump has been eager to reshape the Federal Reserve Board and has hinted that he would like to replace Chairman Jerome Powell before his term ends in 2026. Trump believes the Fed has not been acting quickly enough to lower interest rates and stimulate the economy.

Markets and commodities react

Canadian equity markets were largely unfazed by Canada’s weak GDP data. In fact, the S&P/TSX Composite Index (INDEXTSI:OSPTX) set a new record on Friday, closing the week up 1.73 percent to 28,564.45. The S&P/TSX Venture Composite Index (INDEXTSI:JX) did even better, climbing 5.36 percent to finish Friday at 829.57. The CSE Composite Index (CSE:CSECOMP) fell 0.45 percent on Friday following the StatsCan release, but gained 4.17 percent overall during the week to 166.9.

US equity markets also posted gains this week, but fell from record highs on Friday following a selloff of tech stocks. The S&P 500 (INDEXSP:INX) was up 1.19 percent to 6,460.25, while the Nasdaq 100 (INDEXNASDAQ:NDX) rose 0.99 percent to 23,415.42. Meanwhile, the Dow Jones Industrial Average (INDEXDJX:.DJI) gained 1.32 percent on the week to 45,631.73.

The gold price gained 3.19 percent this week on expectations of a September rate cut by the Federal Reserve, reaching US$3,448.15 per ounce by 4:00 p.m. EDT on Friday. Silver ended the week with a larger gain of 4.2 percent, nearly crossing the US$40 per ounce mark in morning trading before settling at US$39.74 per ounce.

Copper also saw some upward movement, gaining 1.1 percent to US$4.59 per pound. The S&P GSCI (INDEXSP:SPGSCI) commodities index posted an increase of 1.3 percent by close on Friday, finishing at 549.70.

Top Canadian mining stocks this week

How did mining stocks perform against this backdrop?

Take a look at this week’s five best-performing Canadian mining stocks below.

Stocks data for this article was retrieved at 4:00 p.m. EDT on Friday using TradingView’s stock screener. Only companies trading on the TSX, TSXV and CSE with market caps greater than C$10 million are included. Mineral companies within the non-energy minerals, energy minerals, process industry and producer manufacturing sectors were considered.

1. Trifecta Gold (TSXV:TG)

Weekly gain: 117.24 percent
Market cap: C$23.77 million
Share price: C$0.63

Trifecta Gold is a gold exploration company focused on a portfolio of 11 properties in the Tombstone gold belt in the Yukon, Canada.

Its most advanced is its flagship Mt. Hinton gold-silver project, located near Hecla Mining’s (NYSE:HL) Keno Hill silver mine. The company’s project page indicates that vein float samples collected in January 2023 show grades of up to 273 grams per metric ton (g/t) gold.

The company has also been advancing exploration work at its Rye property, which hosts a gold-bismuth soil anomaly, as well as several gold-rich veins.

Shares in Trifecta rose this week alongside news on Thursday that the company had commenced its inaugural drill program at Rye, completing 970 meters across three holes. The announcement reported that the first hole intersected a high density of sheeted quartz veins.

The company said preliminary rock samples collected from the site earlier in 2025 returned multiple assays with greater than 5 g/t gold, including one highlight with 21.1 g/t gold and 8,550 parts per million (ppm) bismuth.

2. Consolidated Lithium Metals (TSXV:CLM)

Weekly gain: 100 percent
Market cap: C$13.98 million
Share price: C$0.04

Consolidated Lithium is an exploration and development company working to advance a portfolio of hard rock lithium projects in Quebéc, Canada.

Its most advanced asset is the Vallée lithium project, a 75/25 joint venture between Consolidated and Sayona Mining (ASX:SAY,OTCQB:SYAXF). The project is located in the Abitibi Greenstone Belt adjacent to and along strike of Sayona’s and Piedmont Lithium (NASDAQ:PLL) North American Lithium mining operation. According to the company’s project page, the Vallée property hosts multiple lithium-bearing pegmatites over a 1 kilometer strike length.

Consolidated announced on Wednesday (August 27) that it signed a letter of intent with the Government of Quebéc-owned Soquem to earn an 80 percent interest in the Kwyjibo rare earth project, located in the Côte-Nord region of the province.

Under the terms of the letter, Consolidated can earn up to an 80 percent interest in the project through two phases, in return for a combination of cash payments, shares in Consolidated and project investments.

A 2017 preliminary economic assessment for Kwyjibo reports project economics including an after-tax net present value of C$373.9 million and an internal rate of return of 17.8 percent, with a payback period of 3.6 years.

3. Electric Metals (TSXV:EML)

Weekly gain: 68.75 percent
Market cap: C$44.34 million
Share price: C$0.27

Electric Metals is a mineral development company focused on advancing its flagship North Star manganese project in Minnesota, US. According to the company, the asset is North America’s highest-grade manganese resource. It plans to produce high-purity manganese sulphate monohydrate for lithium-ion batteries.

The most recent news from Electric Metals was released on Tuesday, when it announced a preliminary economic assessment for the project. The assessment demonstrated a base-case after-tax net present value of US$1.39 billion, with an internal rate of return of 43.5 percent and a payback period of 23 months. and suggested an average annual after-tax cash flow of US$249.6 million.

The report also included an updated mineral resource estimate with an indicated resource of 7.6 million metric tons of ore grading 19.07 percent manganese, 22.33 percent iron and 30.94 percent silicon, and an inferred resource of 3.73 million metric tons of ore grading 17.04 percent manganese, 19.04 percent iron and 30.03 percent silicon.

4. Sage Potash (TSXV:SAGE)

Weekly gain: 58.33 percent
Market cap: C$31.93 million
Share price: C$0.38

Sage Potash is a potash exploration company currently working to advance its portfolio of mineral holdings in Utah’s Paradox Basin in the US.

Historic oil and gas exploration in the basin dating back a century discovered the potential for the potash beds, but they were too deep for mining methods at the time. Sage has since confirmed their presence through its own exploration.

In a revised technical report from February 2023, the company reported an inferred mineral resource estimate of up to 159.3 million metric tons of in-place sylvinite from the upper potash bed and up to 120.2 million metric tons of sylvinite from the lower potash bed.

On August 14, Sage announced that Stockwell Day had joined the company board. Day served several ministerial roles for the Canadian government under Prime Minister Stephen Harper, including as President of the Treasury Board and Minister of International Trade.

This was followed by news on Wednesday that Day had been granted 600,000 stock options at an exercise price of C$0.30 per share and would remain valid for a period of five years.

Sage’s share price spiked earlier this week after the US Government added potash in its draft of an updated list of critical minerals.

5. Kincora Copper (TSXV:KCC)

Weekly gain: 58.33 percent
Market cap: C$24.8 million
Share price: C$0.095

Kincora Copper is an exploration company operating under a project generator model and partnering with other companies to advance its portfolio, including copper-gold projects in the Macquarie Arc of New South Wales, Australia.

Among them is the Northern Junee-Narromine Belt (NJNB) land package, which is covered by a May 2024 earn-in agreement that could see AngloGold Ashanti (NYSE:AU,JSE:ANG) earn up to an 80 percent interest in the Nyngan and Nevertire licenses through AU$50 million in exploration expenditures or AU$25 million for exploration and the completion of a pre-feasibility study.

Kincora secured a second agreement with AngloGold Ashanti in April for the Nyngan South, Nevertire South and Mulla licenses with similar terms, bringing the total exploration funding to AU$100 million.

On Monday (August 25), Kincora announced results from the first drilling program at the Nyngan project, noting that assays support the potential for porphyry copper and epithermal gold, and that it saw ‘encouraging results at particularly shallow depths’ from drill targets identified by a ground gravity survey earlier this year.

Additionally, Kincora said that drilling is ongoing at the Nevertire South and Nevertire projects, with the initial program planned for seven holes and 2,150 meters.

FAQs for Canadian mining stocks

What is the difference between the TSX and TSXV?

The TSX, or Toronto Stock Exchange, is used by senior companies with larger market caps, and the TSXV, or TSX Venture Exchange, is used by smaller-cap companies. Companies listed on the TSXV can graduate to the senior exchange.

How many mining companies are listed on the TSX and TSXV?

As of May 2025, there were 1,565 companies listed on the TSXV, 910 of which were mining companies. Comparatively, the TSX was home to 1,899 companies, with 181 of those being mining companies.

Together, the TSX and TSXV host around 40 percent of the world’s public mining companies.

How much does it cost to list on the TSXV?

There are a variety of different fees that companies must pay to list on the TSXV, and according to the exchange, they can vary based on the transaction’s nature and complexity. The listing fee alone will most likely cost between C$10,000 to C$70,000. Accounting and auditing fees could rack up between C$25,000 and C$100,000, while legal fees are expected to be over C$75,000 and an underwriters’ commission may hit up to 12 percent.

The exchange lists a handful of other fees and expenses companies can expect, including but not limited to security commission and transfer agency fees, investor relations costs and director and officer liability insurance.

These are all just for the initial listing, of course. There are ongoing expenses once companies are trading, such as sustaining fees and additional listing fees, plus the costs associated with filing regular reports.

How do you trade on the TSXV?

Investors can trade on the TSXV the way they would trade stocks on any exchange. This means they can use a stock broker or an individual investment account to buy and sell shares of TSXV-listed companies during the exchange’s trading hours.

Article by Dean Belder; FAQs by Lauren Kelly.

Securities Disclosure: I, Dean Belder, hold no direct investment interest in any company mentioned in this article.

Securities Disclosure: I, Lauren Kelly, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

It’s been a busy week for Cracker Barrel Old Country Store’s marketing team.

The restaurant chain announced a rebrand and new logo last week, faced widespread criticism from social media users, including President Donald Trump, and proceeded to walk back its plan to change the logo.

In that span of time, the company lost and regained almost $100 million in market value, bringing it about back to where it started. The stock gained 8% on Wednesday.

The Cracker Barrel saga is just the latest example of a consumer-facing company making big branding decisions, then pulling back after alienating its customer base.

“It’s very tricky to be a brand for everyone today,” Carreen Winters, president of reputation at the global public relations firm MikeWorldWide, said in an interview. “Legacy brands are particularly tricky, because you have to figure out what is cherished and authentic from the old and marry it with the new.

“In Cracker Barrel’s case, they’re trying to attract a new, younger customer [which] is no longer sufficient,” she continued. “You need to actually think about all of your stakeholders and how they will react, respond, feel about what you’re doing or the direction you’re taking. And you need to be sure that what you’re doing is consistent with shared values.”

Rebranding failures are not a new phenomenon. One of the most famous marketing blunders of all time happened in 1985 when the Coca-Cola company introduced “New Coke” with a new formula. After a firestorm of outrage from its customers, the company returned to its classic formula a few months later.

But social media has made backlash from consumers faster and more widespread, meaning businesses are usually quicker to walk back on their branding failures.

In 2010, retailer Gap ditched its decades-old blue box logo for a more minimalist design. It faced intense backlash on social media through thousands of engagements and, within less than a week, the company said it was reverting to its original logo.

More recently in May, Warner Bros. Discovery announced its streaming platform would undergo another name change, after switching from HBO to HBO Max to Max and then back again to HBO Max.

Major rebrands don’t always go awry. For example, Kentucky Fried Chicken successfully rebranded to KFC in 1991. Its customers already used the acronym and the rebrand signified that the restaurant chain offers more than just fried chicken.

Dunkin’ Donuts also successfully underwent its name change to Dunkin’ in 2019. It did face some criticism from its loyal customers at the time, but Winters said today the “Dunkin’” name and branding are widely accepted over its original name.

“Dunkin’ rebranded in accordance with the behavior that the customer created,” she said. “It aligned with their strategy of being more than Donuts and really building their coffee business.”

She also mentioned IHOP as an example of a brand that has been able to freshen up its look and stay relevant in culture. She said IHOP’s change has been an “evolution, not a revolution.”

Beth LaGuardia Cooper, chief marketing officer at Advantage, The Authority Company, added during an interview that Starbucks had subtle changes to its logo over time, which allowed it to hold the base of its identity close.

While some social media users disliked Cracker Barrel’s new branding simply because they said it lacked substance and was too “sterile” or “soulless,” others, especially conservatives, claimed the new logo leaned into “wokeness” and diversity efforts.

Cracker Barrel is widely considered a classic American restaurant chain. It began in Tennessee in 1969 and its branding evokes Southern charm and nostalgia for its consumer base.

Eric Schiffer, chairman of the firm Reputation Management Consultants, said the new branding, without the iconic “Uncle Herschel” figure, suggested to conservatives that having a white man featured on the logo was wrong or politically incorrect.

He said that pushback represents a larger trend where conservatives are feeling under attack by diversity, equity and inclusion efforts.

“I think the perspective of conservatives is, don’t ruin Cracker Barrel with the Bud Light meets Jaguar marketing playbook,” said Schiffer, adding that those brands “attempted to disrupt positively and what they did was they nuked brand sentiment and shareholder confidence.”

In November, Tata Motors-owned Jaguar Land Rover announced a rebrand that removed its “leaper” big cat imagery from its logo and changed the brand’s font. Its new promotional materials included brightly dressed models, but no cars. The brand faced significant pushback, including tens of thousands of responses on social media.

Elon Musk criticized the company on X at the time, asking Jaguar’s official account: “Do you sell cars?”

Earlier this month, Trump piped in with his insults, calling Jaguar’s ad campaign “stupid” and “seriously WOKE.”

The Telegraph reported in May that Jaguar was searching for a new advertising agency after the public backlash.

Similarly, Anheuser-Busch InBev’s Bud Light faced heavy criticism from conservatives in 2023 after a collaboration between the beer brand and social influencer Dylan Mulvaney, who is transgender.

“If you’re trying to be a tough, male-focused, football fan-oriented beer, the last thing you want to do is put the wrong spokesperson in front of the brand,” Schiffer said. “It will turn off that audience and it allows competitors to capture that market share.”

“The throughline in all of this is, don’t rip apart and disrespect audiences that brought you to the dance,” Schiffer said. “Find a way, if you’re going to want to expand, do it in a way that doesn’t cut at the core of what the brand stands for — and in the process, create cognitive dissonance and blow up market cap.”

Branding experts told CNBC that at the end of the day, people are talking about Cracker Barrel, which is a win for the company by itself.

“Everybody loves a comeback in America,” LaGuardia Cooper said. “So I would root for them to make this happen, make something good out of it.”

This post appeared first on NBC NEWS

The de minimis exemption, an obscure trade law provision that has simultaneously fueled and eroded businesses across the globe, officially came to an end on Friday following an executive order by President Donald Trump.

For nearly a decade, shipments valued under $800 were allowed to enter the country virtually duty free and with less oversight. Now, those shipments from the likes of Tapestry, Lululemon and just about any other retailer with an online presence will be tariffed and processed in the same way that larger packages are handled.

In May, Trump ended the exemption for goods coming from China and Hong Kong, and on July 30 he expanded the rollback to all countries, calling it a “catastrophic loophole” that’s been used to evade tariffs and get “unsafe or below-market” products into the U.S.

The de minimis exemption had previously been slated to end in July 2027 as part of sweeping legislation passed by Congress, but Trump’s executive order eliminated the provision much sooner, giving businesses, customs officials and postal services less time to prepare.

“The ending of that under-$800-per-person-per-day rule, from a global perspective, is about to probably cause a bit of pandemonium,” said Lynlee Brown, a partner in the global trade division at accounting firm EY. “There’s a financial implication, there’s an operational implication, and then there’s pure compliance, right? Like, these have all been informal entries. No one’s really looked at them.”

Already, the sudden change has snarled supply chains from France to Singapore and led post offices across the world to temporarily suspend shipments to the U.S. so they can ensure their systems are updated and able to comply with the new regulations.

It’s forced businesses both large and small to rethink not just their supply chains, but their overall business models, because of the impact the change could have on their bottom lines — setting off a panic in board rooms across the country, logistics experts said.

“Obviously it’s a big change for operating models for companies, not just the Sheins and the Temus, but for companies that have historically had e-com and brick-and-mortar stores,” Brown said.

The change also means consumers, already are under pressure from persistent inflation and high interest rates, could now see even higher prices on a wide range of goods, from Colombian bathing suits to specialty ramen subscription boxes shipped straight from Japan.

The end of de minimis could cost U.S. consumers at least $10.9 billion, or $136 per family, according to a 2025 paper by Pablo Fajgelbaum and Amit Khandelwal for the National Bureau of Economic Research. The research found low-income and minority consumers would feeling the biggest impact as they rely more on the cheaper, imported purchases.

Popularized by Chinese e-tailers Shein and Temu, use of the de minimis exemption has exploded in the last decade, ballooning from 134 million shipments in 2015 to over 1.36 billion in 2024. Prior to the recent change to limit its use, U.S. Customs and Border Protection said it was processing over 4 million de minimis shipments into the country each day.

A 2023 House report found more than 60% of de minimis shipments in 2021 came from China, but because the packages require less information than larger containers, very little information is known about their origins and the types of goods they contain. That opacity is one of the key reasons why both former President Joe Biden and Trump sought to curtail or end the exemption.

Both administrations have said the exemption was overused and abused and that it’s made it difficult for CBP officials to target and block illegal or unsafe shipments coming into the U.S. because the packages aren’t subject to the same level of scrutiny as larger containers.

“We didn’t have any compliance information … on those shipments, and then that is where the danger of drugs and whatnot being in those shipments” comes in, said Irina Vaysfeld, a principal in KPMG’s trade and customs practice.

The Biden administration particularly focused on how the exemption allowed goods made with forced labor to make it into the country in violation of the Uyghur Forced Labor Protection Act. Meanwhile, Trump has said the exemption has been used to ship fentanyl and other synthetic opioids into the U.S. In a fact sheet published on July 30, the White House said 90% of all cargo seizures in fiscal 2024, including 98% of narcotics seizures and 97% of intellectual property rights seizures, originated as de minimis shipments.

Across the globe, it’s common for countries to allow low-value shipments to be imported duty-free as a means to streamline and facilitate global trade, but typically, it’s for packages valued around $200, not $800, said EY’s Brown.

Until 2016, the U.S.’s threshold for low-value shipments was also $200, but it was changed to $800 when Congress passed the Trade Facilitation and Trade Enforcement Act, which sought to benefit businesses, U.S. consumers and the overall U.S. economy, according to the Congressional Research Service. It said higher thresholds provide a “significant economic benefit” to both business and shoppers and thus, the overall economy.

While well-intentioned, the law came with unintended consequences, said Brown.

The “rise in value, from $200 to $800, just made it kind of like a free for all to say, OK, everything come in,” she said.

Eventually companies designed supply chains around the exemption: They set up bonded warehouses, where duties can be deferred prior to export, in places like Canada and Mexico and then imported goods in bulk to those regions before sending them across the border one by one, duty free, as customer orders rolled in, said Brown.

“Companies have really laid out their supply chain in a very specific way [around de minimis] and that’s really the crux of the issue,” said KPMG’s Vaysfeld. “The way that the supply chain has been laid out now may need to change.”

Until the rise of Shein and Temu, the de minimis exemption was rarely discussed in retail circles. Soon, the e-commerce behemoths began facing widespread criticism for their use of what many called a loophole.

In 2023, the House Select Committee on the Chinese Communist Party released a report on Shein and Temu and said the two companies were “likely responsible for more than 30 percent of all packages shipped to the United States daily under the de minimis provision, and likely nearly half of all de minimis shipments to the U.S. from China.”

The revelation sparked widespread consternation among retail executives, lobbyists and government officials who said the companies’ use of the exemption was unfair competition.

However, behind closed doors, companies large and small began mimicking the same model after realizing how it could reduce the steep costs that come along with selling goods online.

Direct-to-consumer companies that only have online presences have relied on it more heavily, so much so that their businesses may not work without it, said Vaysfeld.

“Some of the companies we’ve spoken to, they’ve modeled out, if the tariffs continue for one year, for two years, how does that impact their profitability, and they know how long they can last,” said Vaysfeld. “These aren’t the huge companies, right? These are the smaller companies … Depending on what country they’re sourcing from or where they’re manufacturing, it could really impact their profitability that they can’t stay in business for the long term.”

While smaller, digital companies are more exposed, “pretty much most companies that you can think of” had been using the exemption in some form before it ended, said Vaysfeld.

Take Coach and Kate Spade’s parent company Tapestry: About 13% to 14% of the company’s sales were previously covered under de minimis and will now be subject to a 30% tariff, according to an estimate by equity research firm Barclays.

On the company’s earnings call earlier this month, Chief Financial Officer Scott Roe said tariffs will hit its profits by a total of $160 million this year, including the impact of the end of de minimis. That amounts to about 2.3% of margin headwind, he said.

Shares of the company fell nearly 16% the day that Tapestry reported the profit hit.

In a statement, Roe said Tapestry used de minimis to help support its strong online business, adding it is a practice that “many companies with sophisticated supply chains have been doing for years.”

To help offset its termination, he said Tapestry is looking for ways to reduce costs and is leaning on its manufacturing footprint across many different countries.

Canadian retailer Lululemon is another company that uses de minimis, according to Wells Fargo. Last week, the bank cut its price target on the company’s stock from $225 to $205, citing the end of de minimis. In the note, Wells Fargo analyst Ike Boruchow said the equity research firm sees a potential 90 cent to $1.10 headwind to Lululemon’s earnings per share from the de minimis elimination.

Lululemon declined to comment, citing the company’s quiet period ahead of its reporting earnings.

The National Retail Federation, the industry’s largest trade organization, has not taken a position in favor of or against the exemption. It has members who both supported and opposed the policy, said Jonathan Gold, vice president of supply chain and customs policy at NRF.

Retailers of all sizes, including independent sellers with digital storefronts, have used the approach as “a convenient way to get products to the consumer” for less, Gold said.

“Their costs are going to go up and those costs could be passed on to the consumer at the end of the day,” Gold said.

The most acute impact of the end of de minimis is expected to be felt on online marketplaces where millions of small businesses sell goods like Etsy, eBay and Shopify and used de minimis to defray costs when sending online orders from other parts of the globe to the U.S.

American shoppers have gotten used to buying artwork, coffee mugs, T-shirts and other items from merchants outside the country without paying duties. With that tariff exemption gone, consumers could face higher costs and a more limited selection of items to choose from.

Etsy, eBay and some other retailers sought to defend the loophole prior to its removal, submitting public comments on proposed de minimis regulation by the CBP. An eBay public policy executive said the company was concerned that restrictions to de minimis “would impose significant burdens on American consumers and importers.”

Etsy’s head of public policy, Jeffrey Zubricki, said the artisan marketplace supports “smart U.S. de minimis reform,” but that it was wary of changes that could “disproportionately affect small American sellers.”

“These exemptions are a powerful tool that help small creators, artisans and makers participate in and navigate cross-border trade,” Zubricki wrote in a March letter to CBP.

An Etsy spokesperson declined to comment on the policy change. Etsy CFO Lanny Baker said at a Bernstein conference in May that transactions between U.S. buyers and European sellers comprise about 25% of the company’s gross merchandise sales.

EBay didn’t immediately provide a comment in response to a request from CNBC. The company warned in its latest earnings report that the end of de minimis outside of China could impact its guidance, though CEO Jamie Iannone told CNBC in July that he believes eBay is generally “well suited” to navigate the shifting trade environment.

Some eBay and Etsy sellers based in the UK, Canada and other countries are temporarily closing off their businesses to the U.S. as they work out a plan to navigate the higher tariffs. Blair Nadeau, who owns a Canadian bridal accessories company, was forced to take that step this week.

“This is devastating on so many levels and millions of small businesses worldwide are now having their careers, passions and livelihoods threatened,” Nadeau wrote in an Instagram post on Tuesday. “Just this past hour I have had to turn away two U.S. customers and it broke my heart.”

Nadeau sells her bespoke wedding veils, jewelry and hair adornments through her own website and on Etsy, where 70% of her customer base is in the U.S. The de minimis provision had been a “lifeline” for many Canadian businesses to get their products in the hands of American consumers, Nadeau said in an interview.

“This is really hitting me,” Nadeau said. “It’s like all of a sudden 70% of your salary has been removed overnight.”

In the absence of de minimis, online merchants are faced with either paying import charges upfront and potentially passing those costs on to shoppers through price hikes, or shipping products “delivery duty unpaid,” in which case it’s the customer’s responsibility to pay any duties upon arrival.

Alexandra Birchmore, an artist based in the Cotswolds region of England, said she expects to raise the price of her oil paintings on Etsy by 10% as a result of paying the duties upfront.

“At the moment every small business forum I am on is in chaos about this,” Birchmore said. “It looks to me to be a disaster where no one benefits.”

The disruption could end up being a boon for the likes of Amazon and Walmart. U.S. consumers may turn to major retailers if they face steeper prices elsewhere, as well as potential shipping delays due to backlogs or other issues at the border.

Amazon, in particular, has already proven resilient after the U.S. axed the de minimis provision for shipments from China and Hong Kong in May. The company’s sales increased 13% in the three-month period that ended June 30, compared with 10% growth in the prior quarter. Amazon’s unit sales grew 12%, an acceleration from the first quarter.

Both Amazon and Walmart have fulfillment operations in the U.S. that allow overseas businesses to ship items in bulk and store them in the companies’ warehouses before they’re dispatched to shoppers. Shein and Temu largely eschewed the model in the past in favor of the de minimis exception, but they’ve since moved to open more warehouses in the U.S. in the wake of rising tariffs.

Since the exemption ended on Chinese imports in May, the impact on Shein and Temu has been swift. Temu was forced to change its business model in the U.S. and stop shipping products to American consumers from Chinese factories.

The end of de minimis, as well as Trump’s new tariffs on Chinese imports, also forced Temu to raise prices, reign in its aggressive online advertising push and adjust which goods were available to American shoppers.

The Financial Times reported on Tuesday that Temu has resumed shipping goods to the U.S. from Chinese factories and will also increase its advertising spend following what it called a “truce” between Washington and Beijing.

Temu didn’t return a request for comment.

Meanwhile, Shein has been forced to raise prices and daily active users on both platforms in the U.S. have fallen since the de minimis loophole was closed, CNBC previously reported. Temu’s U.S. daily active users plunged 52% in May versus March, while Shein’s were down 25%, according to data shared with CNBC by market intelligence firm Sensor Tower.

This post appeared first on NBC NEWS

NVIDIA (NASDAQ:NVDA) delivered another blockbuster quarter, reporting record revenue of US$46.7 billion for its second fiscal period as demand for artificial intelligence (AI) infrastructure continues to surge.

The chipmaking giant said sales rose 56 percent from a year earlier and 6 percent from the prior quarter, marking the ninth straight period of year-on-year revenue growth above 50 percent.

Meanwhile, NVIDIA’s net income jumped 59 percent to US$26.42 billion from US$16.6 billion. Its adjusted earnings per share were US$1.05, beating analyst forecasts of US$1.01.

“Blackwell is the AI platform the world has been waiting for, delivering an exceptional generational leap — production of Blackwell Ultra is ramping at full speed, and demand is extraordinary,” said founder and CEO Jensen Huang.

“The AI race is on, and Blackwell is the platform at its center,” he added.

The company’s data center division once again fueled growth as it generated US$41.1 billion in revenue, 56 percent higher than a year ago. Roughly US$33.8 billion of that total came from sales of NVIDIA’s GPUs, while US$7.3 billion was from networking hardware that ties together large AI computing systems.

Sales of NVIDIA’s Blackwell processors, launched in May, rose 17 percent quarter-on-quarter. The product line has quickly become the backbone of NVIDIA’s data center business, accounting for a majority of the segment’s revenue.

Wall Street reacts to NVIDIA results

Despite NVIDIA’s strong numbers, company shares initially slipped in after-hours trading as some investors fretted about slower growth momentum in the data center division.

Regardless, the stock later pared its losses by turning positive on Thursday (August 28).

Overall, NVIDIA has surged 35 percent so far this year after nearly tripling in 2024.

NVIDIA performance, August 25 to 28, 2025.

Chart via Google Finance.

The company is guiding for revenue of US$54 billion, plus or minus 2 percent, in the October quarter.

However, that forecast does not assume any shipments of the H20, a chip that was designed for the Chinese market, but is currently sidelined by export restrictions.

Colette Kress, NVIDIA’s CFO, told analysts the company could ship between US$2 billion and US$5 billion worth of H20 processors this quarter if geopolitical conditions allow.

No H20 sales to China

NVIDIA confirmed it had no H20 sales to China in its second quarter.

Instead, it benefited from releasing US$180 million in previously reserved H20 inventory to a customer outside of China, boosting reported revenue by US$650 million. The company previously said that the lack of H20 shipments cost it up to US$8 billion in potential sales in the second quarter alone.

Huang met with US President Donald Trump earlier this summer to lobby for licenses to export the H20, a chip that was developed specifically to comply with US trade restrictions.

Under a tentative deal, NVIDIA agreed to pay 15 percent of China H20 revenue to the US government in exchange for export approvals. However, the arrangement has yet to be codified into a formal agreement.

Blackwell and the China dilemma

Beyond H20, attention has shifted to NVIDIA’s newest flagship processor, Blackwell.

On Wednesday’s (August 27) earnings call, Huang said there is “a real possibility” of bringing Blackwell to China.

“We just have to keep advocating the importance of American tech companies to be able to lead and win the AI race, and help make the American tech stack the global standard,” he said. Huang estimates that China represents a US$50 billion opportunity for NVIDIA this year, with growth of 50 percent annually. He argued it is better for Chinese AI firms to use NVIDIA chips, even if modified, rather than being forced to rely on domestic alternatives.

Trump, however, has expressed caution. Speaking at a press conference earlier this month, he said, “The Blackwell is super-duper advanced. I wouldn’t make a deal with that.”

However, he said he could allow a “somewhat enhanced in a negative way” Blackwell chip to be sold to China, further suggesting that such a version could be slowed by 30 to 50 percent to comply with US restrictions.

Even without China sales, NVIDIA maintains a bright outlook.

Huang told analysts the buildout of AI infrastructure is still in its early stages, further projecting that global spending on AI infrastructure could reach US$3 trillion to US$4 trillion by the end of the decade.

Furthermore, large cloud providers, which remain NVIDIA’s biggest customers, have announced plans to spend tens of billions of dollars per quarter on AI infrastructure, ensuring a steady pipeline of demand for the company’s chips.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Investor Insight

Cobre offers investors a rare combination of district-scale copper-silver discovery potential, near-term development upside through its ISCR-ready Ngami copper project, and a capital-light growth model underpinned by major-partner funding and diversified exposure to critical minerals.

Overview

Cobre (ASX:CBE) is an Australian exploration company unlocking the copper-silver potential of the Kalahari Copper Belt in Botswana, one of the world’s most prospective but underexplored sediment-hosted copper provinces. With approximately 5,348 sq km of land position, the company’s near-term focus is the Ngami copper project (NCP), where a maiden JORC resource at the Comet deposit establishes an initial copper-silver resource with strong in-situ copper recovery (ISCR) development credentials.

Cobre’s project location in the Kalahari Copper Belt

Cobre’s growth strategy balances district-scale discovery potential with development-ready assets, leveraging major-partner funding, including up to AU$40 million (US$25 million) investment from BHP to accelerate exploration at Kitlanya, while concentrating company capital on advancing NCP through technical, environmental and permitting milestones. The company complements its Botswana assets with strategic exposure to high-purity quartz and volcanogenic massive sulphide (VMS) opportunities in Western Australia. This diversified, capital-light approach aims to build shareholder value through discovery, derisking and development optionality.

Company Highlights

  • Dominant land position – ~5,348 sq km across Botswana’s Kalahari Copper Belt (KCB), the second largest tenement package in the districtInvestor
  • Maiden JORC Mineral Resource – Comet deposit (Ngami copper project): 11.5 Mt @ 0.52 percent copper and 11.6 grams per ton (g/t) silver (60.3 kt copper; 4.3 Moz silver), incl. 1.1 Mt indicated @ 0.59 percent copper and 12.8 g/t silver
  • BHP partnership – Eight-year earn-in across Kitlanya East & West, allowing BHP to earn 75 percent by providing up to US$25 million for exploration expenditure, while Cobre retains exposure
  • BHP Xplor cohort – Selected in 2024, securing US$500,000 non-dilutive funding and technical support
  • Multi-jurisdiction exploration portfolio – Botswana (copper-silver), Western Australia (VMS, high-purity quartz)

Key Projects

Ngami Copper Project

The 100 percent owned Ngami copper project is Cobre’s flagship asset and the primary focus of current exploration and technical work. Situated in the Kalahari Copper Belt (KCB), NCP spans multiple licences covering highly prospective sediment-hosted copper-silver targets along basin margins.

Comet Deposit – Maiden JORC Resource

  • Announced in August 2025, the Comet deposit hosts 11.5 Mt @ 0.52 percent copper and 11.6 g/t silver, including 1.1 Mt indicated @ 0.59 percent copper and 12.8 g/t silver, at a 0.2 percent copper cut-off.
  • Contained metal: ~60,300 tonnes copper and 4.3 Moz silver.
  • Mineralisation is predominantly fine-grained chalcocite, an ideal feedstock for hydrometallurgical processing.

In-Situ Copper Recovery Development Potential

ISCR is a low-cost, low-impact method of producing copper by circulating a solution through the orebody underground to dissolve and pump the metal to surface for processing. For Cobre’s Ngami project, ISCR offers the potential to unlock value without the expense and disruption of conventional mining, thanks to favourable geology, high recoveries in test work, and minimal surface disturbance – positioning it as a potentially faster, cleaner and more capital-efficient path to production.

Exploration Upside

Beyond the initial Comet resource, Ngami hosts extensive growth potential with 40 km of mineralised strike and large, defined exploration targets that could significantly expand the resource base. Early drilling at new zones, such as the Cosmos target, has intersected high-grade copper. More than 20 km of prospective contact remains untested, offering multiple opportunities for further discoveries that could enhance scale, mine life and project economics.

Kitlanya East & West

Cobre’s Kitlanya East and West licences, also located in Botswana, involve an eight-year earn-in agreement with BHP. Under the deal, BHP can invest up to US$25 million to earn a 75 percent interest in Kitlanya, allowing the company to leverage a major partner’s technical expertise and funding while retaining exposure to potential tier-one discoveries. Exploration is targeting preserved fold hinge settings along basin margins – geological positions known to host large sediment-hosted copper deposits – using advanced geophysics and seismic techniques to define high-priority drill targets.

Okavango Copper Project

Another Botswana copper asset, the Okavango project is located along strike from MMG’s Zone 5 deposit. Okavango offers 186 km of prospective contact in the northeast Kalahari Copper Belt. Early drilling has intersected multiple zones of anomalous copper and silver mineralisation, and geophysical data shows gravity signatures comparable to those in producing areas, indicating strong potential for significant new discoveries.

Perrinvale Project

In addition to its African portfolio, Cobre holds the Perrinvale project in Western Australia, prospective for both high-grade VMS mineralisation and high-purity quartz (HPQ). The HPQ target has an exploration range of 5.1 to 28.3 Mt grading 99.1 to 99.6 percent SiO₂, positioning it as a potential supplier to critical silicon markets for renewable energy and electronics.

Management Team

Martin Holland – Executive Chairman

Martin Holland is the founder of Cobre and co-founder of multiple ASX-listed companies, including Lithium Power International. He has more than 15 years’ experience in capital markets and resource company leadership, raising more than AU$200 million for exploration.

Adam Wooldridge – Chief Executive Officer

Founding partner and CEO of KML, Adam Woolridge has more than 28 years’ experience in exploration management and target generation in Africa, the Middle East and Europe.

Ross McGowan – Non-executive Director

CEO of Armada Metals and founder of RED Group, Ross McGowan has over 20 years of experience in African exploration, and was part of the Kamoa discovery team.

Michael McNeilly – Non-executive Director

Michael McNeilly, is a corporate financier and CEO of Strata Plc, with experience across multiple listed resource companies.

Michael Addison – Non-executive Director

Michael Addison is the founder of Endocoal, Carabella Resources and Genex Power, with extensive mining and energy development background.

Andrew Sissian – Non-executive Director

Andrew Sissian is co-founder of Cobre and Procon Telematics. He is a corporate and capital markets specialist with a CPA background.

This post appeared first on investingnews.com

North Shore Uranium Ltd. (TSXV:NSU) (‘North Shore‘ or the ‘Company‘) is pleased to announce that it has closed the non-brokered private placement as previously announced on August 7, 2025 (the ‘Offering‘), through the issuance of 24,055,000 non-flow-through units (the ‘NFT Units‘) at a purchase price of $0.05 per NFT Unit and 3,034,922 flow-through units (the ‘FT Units‘) at a purchase price of $0.065 per FT Unit for total aggregate gross proceeds of $1,400,020.

The Company also announces it has entered into a definitive option agreement (the ‘Option Agreement‘) with Resurrection Mining LLC (‘Resurrection‘), an arm’s length party, to acquire up to 87.5% of the Rio Puerco uranium project (‘Rio Puerco‘ or the ‘Project‘) located in northwestern New Mexico (the ‘Transaction‘). The signing of a binding term sheet (the ‘Term Sheet‘) was announced on June 24, 2025.

Brooke Clements, President and CEO of North Shore stated: ‘This is a very exciting milestone for North Shore. The private placement was significantly oversubscribed and we would like to thank our existing shareholders and new shareholders for their support. The Rio Puerco project in New Mexico hosts a significant historical uranium resource and offers us exposure to a uranium project in the USA with excellent upside, at a time when the US government is increasing its support for the nuclear power and uranium mining sectors. The Company plans to work towards confirming and expanding upon previous work at Rio Puerco while further assessing the potential for in-situ uranium recovery. North Shore now has uranium exposure in two North American jurisdictions that have seen significant uranium production, the Grants Uranium District in New Mexico and the Athabasca Basin in Saskatchewan, at a time when the world is moving to increase its reliance on nuclear power.’

$1.4 Million Private Placement

Each NFT Unit consists of one non-flow-through common share and one-half of one share purchase warrant (each whole share purchase warrant, a ‘Warrant‘). Each FT Unit consists of one flow-through common share and one-half of one Warrant. Each Warrant entitles the holder to purchase one non-flow through common share (each a ‘Warrant Share‘) at a price of $0.10 per Warrant Share for a period of two years from the date of closing the Offering.

The net proceeds of the Offering will be used to complete the Transaction, exploration of the Project, continued exploration of the Company’s Saskatchewan uranium properties, the costs of the Offering and for general working capital.

In connection with the Offering, the Company paid cash finder’s fees of $13,500 and issued 228,462 non-transferable finder’s warrants to certain arm’s length finders. The non-transferable finder’s warrant is exercisable to acquire one common share of the Company at a price of $0.10 per share for a period of two years from the date of closing the Offering.

All securities issued in connection with the Offering are subject to a four-month and one-day hold period from the date of closing the Offering. The Offering is subject to the final approval of the TSX Venture Exchange (the ‘Exchange‘).

The completion of the Offering satisfied a closing requirement of the Transaction which required the Company to complete a financing raising a minimum of $750,000.

Insider Participation

Brooke Clements, Director, President and CEO of the Company, James Arthur, a Director of the Company, and Doris Meyer, a Director of the Company, participated in the Offering. These purchases constitute as related party transactions pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (‘MI 61-101‘). There has not been a material change in the percentage of the outstanding securities of the Company that are individually or beneficially owned by Messrs. Clements or Arthur, or Ms. Meyer as a result of their participation in the Offering. The Company is exempt from the requirements to obtain a formal valuation and minority shareholder approval in connection with the participation of the insiders in the Offering in reliance of the exemptions contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, as the fair market value of the insider participation does not exceed 25% of the Company’s market capitalization as determined in accordance with MI 61-101.

The Company obtained approval by the board of directors of the Company of the Offering, with Messrs. Clements and Arthur, and Ms. Meyer declaring and abstaining from voting on the resolutions approving the Offering with respect to their participation in the Offering. No materially contrary view or abstention was expressed or made by any director of the Company in relation thereto.

Rio Puerco Option Agreement

Upon closing of the Offering, and thereby satisfying the financing requirement of the Transaction, the Company entered into the Option Agreement with Resurrection to acquire up to 87.5% of the Project. The terms of the Option Agreement are substantively the same as the terms of the Term Sheet which was announced on June 24, 2025.

Pursuant to the Option Agreement, the Company paid Resurrection a cash payment of $125,000 and issued Resurrection 7,483,000 common shares in the capital of the Company (the ‘Common Shares‘) at a deemed issue price of $0.05, so that Resurrection holds 9.99% of the Common Shares post-Offering, satisfying the Company’s Milestone 1 obligations. The 7,483,000 Common Shares issued will bear a legend restricting trading for a period of two years from the date of issuance.

The remaining milestones and key terms of the Option Agreement are as follows:

  • Milestone 2, to earn a 40% interest in the Project: on or before 18 months after completion of the Transaction, a $250,000 payment in cash or Common Shares, at the option of North Shore, and $750,000 in exploration expenditures.
  • Milestone 3, to earn an aggregate 65% interest in the Project: on or before 36 months after completion of the Transaction, a $375,000 payment in cash or Common Shares, at the option of North Shore, and $1,000,000 in additional exploration expenditures.
  • Milestone 4, to earn an aggregate 87.5% interest in the Project: on or before 60 months after completion of the Transaction, a $500,000 payment in cash or Common Shares, at the option of North Shore, and $1,500,000 in additional exploration expenditures.
  • North Shore may elect to not continue to sole-fund exploration expenditures at any time after earning a 40% interest in Rio Puerco at which time North Shore and Resurrection will enter into a joint venture agreement to govern the funding of Rio Puerco on a proportional basis.
  • Bonus payments: For the 78-month period after completion of the Transaction, North Shore will pay Resurrection $100,000 or issue Common Shares of the same value as a bonus (the ‘Bonus Payment‘) for each million lbs. of uranium estimated in current resources defined by the Company above 5 million and up to 20 million lbs. in accordance with NI 43-101 standards, if and when such resources are defined.
  • Other terms: Resurrection shall have a participation right to maintain its 9.99% interest in the Common Shares of North Shore for 5 years from completion of the Transaction and the right, but not the obligation, to appoint one nominee to the North Shore Board of Directors. All share issuances will be subject to Canadian and US securities law and will be priced in accordance with Exchange policies.

The Transaction constituted an ‘Expedited Acquisition’ in accordance with Exchange policies. All Common Shares issued and issuable under the Option Agreement will be issued with a restrictive period of four months and one day. The minimum deemed share price of any Common Share issuance is $0.05 and will be priced in accordance with the Exchange policies. There were no finder’s fees payable in connection with the Option Agreement.

Technical disclosure on the Property can be found in the Company’s news release dated June 24, 2025.

Caution to US Investors

The securities referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the ‘U.S. Securities Act‘) or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration under the U.S. Securities Act and applicable state securities laws, unless an exemption from such registration is available. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements. ‘United States’ and ‘U.S. person’ have the respective meanings assigned in Regulation S under the U.S Securities Act.

ABOUT NORTH SHORE

The nuclear power industry is in growth mode as more nuclear power will be required to meet the world’s ambitious CO2 emission-reduction goals and the needs of new power-intensive technologies like AI. In this environment, new discoveries of economic uranium deposits will be very valuable, especially in established uranium-producing jurisdictions like Saskatchewan and New Mexico. North Shore is well-positioned to become a major force in exploration for economic uranium deposits. The Company is working to achieve this goal by exploring its Falcon and West Bear properties at the eastern margin of the Athabasca Basin in Saskatchewan, expanding its exploration efforts to include the Grants Uranium District in New Mexico and by evaluating other quality opportunities in the United States and Canada to complement its portfolio of uranium properties. North Shore summarized its exploration efforts at its Falcon property in the Company’s May 27, 2025 news release. For more information about the Rio Puerco property, see the Company’s June 24, 2025 news release.

ON BEHALF OF THE BOARD

Brooke Clements,
President, Chief Executive Officer and Director

For further information:
Please contact: Brooke Clements, President, Chief Executive Officer and Director
Telephone: 604.536.2711
Email: b.clements@northshoreuranium.com
www.northshoreuranium.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking statements that are based on the Company’s current expectations and estimates. Forward-looking statements are frequently characterized by words such as ‘plan’, ‘project’, ‘appear’, ‘interpret’, ‘coincident’, ‘potential’, ‘confirm’, ‘suggest’, ‘evaluate’, ‘encourage’, ‘likely’, ‘anomaly’, ‘continuous’ and variations of these words as well as other similar words or statements that certain events or conditions ‘could’, ‘may’, ‘should’, ‘would’ or ‘will’ occur. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements. Such factors include, among others: the highly speculative nature of the Property given the early-stage nature of Rio Puerco; the ability of the Company to meet the Milestones; the ability of the Company to acquire up to 87.5% of the Project; the creation of a joint venture between the Company and Resurrection; the Bonus Payment to Resurrection; the actual results of current and planned exploration activities including the potential for the definition of a mineral deposit of potential economic value at the Company’s Falcon property in Saskatchewan and Rio Puerco in New Mexico; that drilling results, geophysical survey results and/or interpretations thereof define potentially mineralized corridors; results from future exploration programs including drilling; interpretation and meaning of completed and future geophysical surveys; conclusions of future economic evaluations; changes in project parameters as plans to continue to be refined; possible variations in grades of mineralization and/or future actual recovery rates; accidents, labour disputes and other risks of the mining industry; the availability of sufficient funding on terms acceptable to the Company to complete the planned work programs; delays in obtaining governmental approvals or financing; and fluctuations in metal prices. There may be other factors that cause actions, events or results not to be as anticipated, estimated, or intended. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events, or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Source

Click here to connect with North Shore Uranium (TSXV:NSU) to receive an Investor Presentation

This post appeared first on investingnews.com

KoBold Metals, a US-backed mining firm supported by billionaires Jeff Bezos and Bill Gates, has received seven new permits to explore for lithium in the Democratic Republic of Congo (DRC).

The DRC mining registry confirmed on Wednesday (August 27) that the permits cover ground in both the Tanganyika and Haut-Lomami provinces, including four in Manono territory, home to the massive Roche Dure lithium deposit.

The approvals follow a July agreement between KoBold and the DRC government that positioned the company to acquire and develop the disputed Manono project, considered one of world’s largest untapped lithium deposits.

“Our exploration efforts across all seven new licenses will be focused on lithium,” a KoBold official told Reuters. The permits also authorize searches for coltan, rare earths and other minerals across more than a dozen prospective sites.

For the DRC, the deal with KoBold furthers its strategy to attract western capital and technology to its critical minerals sector, reducing reliance on Chinese firms that dominate much of the country’s cobalt and copper production.

President Félix Tshisekedi publicly endorsed the agreement in July, framing it as a cornerstone of the DRC’s ambitions to strengthen its role in global electric vehicle supply chains.

Betting on AI-driven exploration

Founded in 2018 and backed by Breakthrough Energy Ventures, KoBold counts Bezos, Gates and venture firm Andreessen Horowitz among its investors. The company touts its use of artificial intelligence (AI) and advanced computing technology to accelerate the search for copper, cobalt, nickel and lithium.

Under its July framework with Kinshasa, California-based KoBold committed to launching a large-scale exploration program across more than 1,600 square kilometers by mid-2025. The agreement also obliges the DRC to appoint a special envoy to facilitate KoBold’s pursuit of the Manono acquisition.

In addition to field exploration, the company has pledged to digitize geological records housed at Belgium’s Royal Museum of Central Africa and make them publicly accessible through the DRC’s National Geological Service.

Legal clouds over Manono

Despite KoBold’s focus on Manono, the asset is mired in a protracted legal battle.

AVZ Minerals (ASX:AVZ), through its local joint venture Dathcom Mining, argues that it remains the rightful permit holder and has taken its case to the International Center for Settlement of Investment Disputes.

Last year, the tribunal issued interim measures ordering the DRC to recognize AVZ’s rights pending a final ruling.

AVZ said the KoBold agreement, which covers parts of the same perimeter, breaches those orders.

In a July 21 statement, the company stressed that it “remains open to constructive dialogue,” but insisted that any outcome must respect its legal rights and existing relationships.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Elon Musk’s Neuralink has captured the public’s attention and imagination with its futuristic vision of connecting the human brain to computers.

A July 2024 report by IDTechEx projects that the overall brain computer interface (BCI) market could reach a market value of over US$1.6 billion by 2045.

‘We anticipate that the market for non-invasive solutions will grow before the commercialization of invasive solutions from players such as Neuralink,’ stated the research firm’s Senior Technology Analyst Dr. Tess Skyrme. ‘However, the long-term opportunity within the assistive technology market is more likely to be captured by the likes of Elon Musk.’

As Neuralink continues to make strides, investors are wondering how to get a piece of the action by investing in the neurotechnology venture.

Because it is privately held, Neuralink stock isn’t accessible to the average person — but that doesn’t mean its impossible to get exposure to this future-looking medical research company. Read on to learn how to participate in the growth of this exciting business.

In this article

    What is Neuralink?

    Neuralink is a neurotechnology startup that was founded in 2016 by Tesla (NASDAQ:TSLA) CEO Musk and a team of eight scientists and engineers in 2016.

    It was first reported on in 2017, and two years later, in June 2019, the company held and streamed its public launch event to showcase the technology it is developing: an innovative brain-computer interface.

    Instead of using traditional electrodes, which according to a company whitepaper can be bulky and damaging to brain tissue, Neuralink’s BCI uses “ultra-thin threads” that are implanted into the brain using a robotic device that resembles a sewing machine. Once implanted, the electrodes develop a BCI, stimulating the brain and monitoring activity, and the threads connect to a custom-designed chip that can read data from groups of neurons.

    Potential uses of BCI technology include helping paralyzed individuals regain control of their limbs and restoring vision. Musk told his audience during Neuralink’s 2019 launch event that this technology could have a wide range of applications in medicine, such as restoring sensory and motor function in people with spinal cord injuries or neurological disorders. Additionally, an early goal of development is translating neuron signals into computer commands, which would allow humans to control devices like computers and smartphones with their brainwaves.

    Musk has claimed that BCI could even facilitate direct communication between humans and machines, although some members of the neuroscientific community are skeptical. Other experts have suggested that Neuralink’s work is not necessarily novel — as Dr. Jason Shepherd, an associate professor of neurobiology at the University of Utah, told Business Insider in 2020, “All the technology that he showed has been already developed in some way or form. Essentially what they’ve done is just package it into a nice little form that then sends data wirelessly.”

    Other experts in the field have ethical concerns about how Neuralink is conducting its clinical trials and the broader implications of disregarding established standards.

    “If you decide to play with fire in a house, you increase the risk threshold not only of yourself but of the whole house,” Marcello Ienca, a professor of ethics of AI and neuroscience at Technical University of Munich, told Forbes. “My fear is that Neuralink’s disregard for the ethical aspects of their technology may cause a backfire effect for the entire neurotechnology community.”

    How much is Neuralink worth?

    Neuralink was reportedly valued at around US$9 billion in May 2025, but as a privately held business, much of its financial information is kept under wraps. That said, US Securities and Exchange Commission (SEC) documents containing information about its funding rounds provide some insight.

    The earliest came in 2017, when the company raised US$27 million out of a planned US$100 million in a Series A funding round. In April 2019, SEC filings show the company acquired US$39 million out of a planned US$51 million in a Series B funding round. A limited amount of information has been made available to the public, and the identities of the investors have not been publicly disclosed. However, some news outlets have speculated that funding could have come from a combination of venture capitalists, or from Musk himself and the Neuralink team.

    In 2021, Neuralink received what was then its largest amount of money to date, raising US$205 million in a funding round led by tech investment firm Vy Capital. Other participants included Google Ventures, the venture capital arm of Alphabet (NASDAQ:GOOGL); OpenAI CEO Sam Altman; Fred Ehrsam, co-founder of Paradigm and Coinbase Global (NASDAQ:COIN); and Ken Howery, co-founder of PayPal Holdings (NASDAQ:PYPL) and Founders Fund.

    In May 2023, as Neuralink faced public backlash over accusations of animal mistreatment, it received clearance from the US Food and Drug Administration (FDA) to run the first human trial of its brain implant. Just months later, in August, Neuralink closed a US$280 million funding round led by Founders Fund. The filing was amended in November 2023 to reflect an additional US$43 million, bringing the total to US$323 million.

    Most recently, the company announced the closure of a US$650 million Series E funding round in June 2025.

    Is Neuralink approved for human trials?

    In May 2023, the US Food and Drug Administration granted Neuralink clearance to run the first human trials of its brain implant, and Health Canada approved Neuralink brain-computer implant clinical trials in November 2024.

    During the company’s summer update meeting in July 2025, it was revealed that a total of nine human clinical trial participants have received the Neuralink implant. A subsequent study was launched in Great Britain in July 2025, and the company said it will soon begin a trial to help restore sight to the blind in the United Arab Emirates.

    Neuralink has so far made the most progress with its US clinical trial. The company opened a patient registry in early 2023 that allowed people who had at least one of a qualifying list of conditions to volunteer for upcoming clinical trials.

    The first study, dubbed PRIME — Precise Robotically Implanted Brain-Computer Interface — is specifically focused on patients with cervical spinal cord injuries or amyotrophic lateral sclerosis. It has an estimated primary completion date of January 2026 and is estimated to be fully completed by January 2031.

    Musk said in January 2024 that the brain chip being used for testing is named Telepathy. It is about the size of a coin, and each one is equipped with over 1,000 electrodes 20 times finer than human hair that fan out into the cerebral cortex. The first operation was performed on January 29, 2025. Musk shared the results on X, formerly known as Twitter, stating that the patient was “recovering well” and that “initial results show promising neuron spike detection.”

    The next update came during a Spaces event on X on February 19, 2024, during which Musk stated that the patient had recovered and was able to move a computer cursor using thought. In mid-May, Neuralink’s first patient, Noland Arbaugh, who is quadriplegic, shared his experiences in his first 100 days with the Neuralink brainchip.

    According to Arbaugh at the time, despite some setbacks, he believed his trial to be a success. One of the largest benefits was that the Link allowed him to operate his computer and other devices lying down, while he needed assistance for setup and repositioning with prior devices. This gives him more freedom to live on his own time, he explained. Additionally, it offers greater control than other devices he has used.

    ‘The games I can play now are leaps and bounds better than previous ones,’ Arbaugh said. ‘I’m beating my friends in games that as a quadriplegic I should not be beating them in.’

    Reuters reported in May 2024 that Neuralink would enroll another three patients in its clinical trial. The company has since implanted a brain chip into two additional patients, one who became paralyzed following a spinal cord injury from a diving accident and another who lost use of his limbs to amyotrophic lateral sclerosis (ALS). The company issued an update on their progress in February 2025, with all three patients touting positive changes following the procedure.

    How to invest in Neuralink?

    With Neuralink continuing to move forward, how can investors get a piece of this up-and-coming technology?

    As mentioned, the firm has yet to go public, so purchasing Neuralink stock is not an option for many investors. The vast majority of Neuralink’s funding has come from venture capitalists and a handful of billion-dollar companies.

    However, there are still ways for investors to potentially profit from Neuralink’s growth before it goes public. For example, investing in publicly traded companies that have invested in Neuralink can provide an indirect stake. Many of the company’s investors are venture capital firms or private individuals, but some of these firms, such as Google Ventures, are subsidiaries of publicly traded companies. By investing in Alphabet, individuals can indirectly benefit from its investment in Neuralink, as any profit from the investment could potentially flow back to Alphabet.

    This indirect approach can be a viable strategy for individuals who want to gain exposure to Neuralink without waiting for the company to go public. Coinbase is another company that offers indirect exposure to Neuralink’s growth; the enterprise is owned by Ehrsam, whose venture capital fund Paradigm has invested in Neuralink.

    Those who qualify as accredited investors could also potentially invest in a Neuralink funding round. According to the SEC, an accredited investor must have a net worth of at least US$1 million, not including the value of their primary residence, or an annual income of at least US$200,000 for individuals and US$300,000 for married couples. There must also be a reasonable expectation of the same level of income in the year of filing.

    Individuals can also qualify as accredited investors if they are investment professionals in good standing. In that case, the SEC’s guidelines indicate that they need to hold either a general securities representative license, an investment advisor representative license or a private securities offerings representative license.

    Entities like banks, insurance companies or investment firms with total assets of at least US$5 million may also qualify as accredited investors. Certain types of entities, such as private business companies and small business investment companies, may be exempt from the standard asset value requirements for accredited investor status.

    It’s also worth noting that Neuralink is just one of several companies currently working on developing BCI technology. According to research by IDTechEx, companies working to develop invasive brain-computer interface solutions have amassed nearly US$1.5 billion in funding.

    One competitor is Synchron, a company with similar ambitions that has received funding from the likes of Jeff Bezos and Bill Gates. On February 1, 2024, Synchron acquired a minority stake in German manufacturer Acquandas. This acquisition secures exclusive access to Acquandas’ advanced metal layering technology, which is a critical component for Synchron’s device, the Synchron Switch.

    Synchron launched a patient registry in April 2024 to prepare for an upcoming large-scale brain implant trial required to apply for US Federal Drug Administration (FDA) medical device approval. In July, the company announced that one of the patients implanted with the Synchron BCI was able to use his direct thoughts to control the cursor on the Apple Vision Pro. A year later, Synchron publicly demonstrated the first-ever use of a thought-controlled iPad, using Apple’s BCI Human Interface Device (BCI HID) input protocol that allows a person to control the device with just their thoughts.

    Earlier this year Synchron announced a partnership blending NVIDIA’s (NASDAQ:NVDA) Holoscan platform with its BCI technology. “Synchron’s vision is to scale neurotechnology to empower humans to connect to the world, and the NVIDIA Holoscan platform provides the ideal foundation,” Synchron CEO and Founder Tom Oxley stated.

    The company has since revealed that its implantable BCI is now powered by Chiral AI, a proprietary foundation model of cognition that is trained directly on neural data. This allows its system to move from simple intent recognition to more advanced, self-learning cognitive AI.

    Precision Neuroscience is another company working in the brain-computer interface field, although it is also private. Founded by one of Neuralink’s co-founders, the BCI company is currently testing its Layer 7 Cortical Interface, which is a thin, flexible film that sits on a brain’s gray matter instead of being implanted in it, making it less invasive.

    Precision Neuroscience recently set a record for the highest number of electrodes used to detect a person’s thoughts at 4,096 when they combined four of their interfaces on one brain. The company completed a funding round of US$102 million in December 2024.

    In April 2025, Precision Neuroscience received 510(k) clearance from the FDA for its Layer 7 Cortical Interface, authorizing it for commercial use for up to 30 days. This clearance allows the company to use its technology for intraoperative brain mapping and to build a large repository of neural data.

    A newer market entrant, Merge Labs, is set to receive funding at a US$850 million valuation from OpenAI. Sam Altman will reportedly be a co-founder, according to a report from The Financial Times.

    Although the field is nascent, the potential for BCI to impact various industries such as robotics, medicine and biotech has generated a growing amount of interest and excitement. Additionally, heightened interest in the artificial intelligence (AI) sector has led to more research and exploration in related fields, and has attracted increased investment in fields benefiting from AI advancements, including robotics and medicine.

    AI is also being used as a tool to help discover new insights and make moves that might not have been possible without its use. Scientists in California have even developed a brain implant capable of decoding and vocalising inner speech.

    Finally, one of the simplest ways to gain exposure to Neuralink would be through an exchange-traded fund (ETF) that invests in companies related to BCI technology. While there isn’t an ETF that exclusively focuses on BCIs, there are funds that offer exposure to related themes. One example is the iShares Healthcare Innovation ETF (LSE:HEAL,OTC Pink:BLKIF). This fund consists of companies that are developing new and innovative healthcare technologies.

    Two other options are the Global X Robotics & Artificial Intelligence ETF (NASDAQ:BOTZ), which includes companies that are involved in the development of robotics and AI, and the ARK Innovation ETF (ARCA:ARKK), which focuses on disruptive technologies across multiple industries, including healthcare and robotics.

    As with any investment decision, it’s important to perform due diligence on available options, including comparing ETFs, to ensure they align with one’s investment goals.

    Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

    This post appeared first on investingnews.com

    Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on through generations. So what is genetics investing?

    When it comes to genetics investing, companies in this niche of the life science sector are mostly focused on four submarkets: DNA sequencing, genetic testing, gene therapy and genomics, which includes gene editing.

    This life sciences submarket has gained much attention from investors over the past several years. It has provided a launching pad for a number of biotech firms developing and commercializing novel treatments and drugs addressing a wide range of diseases with unmet needs.

    For those looking to dive into the genetics sector, there are numerous investment opportunities to consider. Investing in gene stocks is the most common route, but there are risks due to the market’s volatility, especially when it comes to wins or losses with the US Food and Drug Administration (FDA).

    Exchange-traded funds (ETFs) are another popular option for gaining exposure to the industry, and come with less risk than investing in a single stock.

    In this article

      What are the key areas of the genetics sector?

      Before diving into investment opportunities in the genetics market, it’s important to understand the industry and the key areas of genetics mentioned above.

        What investors should know about the genetics market

        In the biotech sector, gene therapy is one of the more advanced treatment options, and gene therapy pipeline candidates are robust in late-stage clinical trials.

        In terms of what will — and already has — disrupted the genetics industry, CRISPR gene-editing technology has been on the rise for quite some time. It uses short repeating DNA sequences with “spacers” dividing them to treat genetic diseases.

        While the use of the technology is still in its early stages, in the coming years it’s expected to have a big impact on how genetic diseases are treated, and there are a range of clinical trials underway involving CRISPR technology. So far, the only FDA approved CRISPR-based medicine is Casgevy, developed by Vertex Pharmaceuticals (NASDAQ:VRTX) and CRISPR Therapeutics (NASDAQ:CRSP). It was originally approved in late 2023 for the treatment of sickle cell disease.

        The prominence of gene therapies in the life science sector was a major theme at the 2025 JPMorgan Healthcare Conference in January 2025. Peter Marks, then-director of the FDA’s Center for Biological Evaluation and Research, told attendees that his agency is aiming to accelerate approvals for gene therapies.

        In 2024, the FDA expanded approvals for CRISPR-based Casgevy to beta-thalassemia, and it also approved Pfizer’s (NYSE:PFE) Beqvez and PTC Therapeutics’ (NASDAQ:PTC) Kebilidi.

        Despite experiencing a challenging year in 2024, there is still a lot of optimism in the gene therapy sector. Also speaking at the January conference, Alliance for Regenerative Medicine president Tim Hunt said he believes 10 new cell and gene therapy treatments could reach blockbuster status by 2030.

        “No one’s saying there aren’t headwinds, but we are seeing important signs of growth,” he added.

        Looking at DNA sequencing, this market is driven by advances in biotech, the increasing prevalence of cancer and rising demand for precision medicine, as well as higher investment in research and development. DNA sequencing has become a vital component of this growth and has played a key role in remodeling molecular biology and genomics research.

        Genetic testing is another segment of the genetics industry that is growing at a fast pace. Unsurprisingly, technological breakthroughs have had a huge impact on genetic testing, and so has the fact that governments and regulatory bodies are turning their attention to this market in order to regulate and raise awareness to treat diseases such as cancer, cystic fibrosis and sickle cell anemia.

        Biotech and pharmaceutical companies are also expressing interest in this sector, which is expected to further fuel genetics sector growth in the coming years. Mergers and acquisitions activity is also expected to increase as companies seek to expand their product portfolios new candidates and technologies.

        As can be seen, the genetics industry is vast and complex, but is also ripe with investment opportunities.

        How to invest in gene stocks

        Investors looking to invest in the field of genetics through stocks have many options, from large-cap biotech companies to pure-play gene therapy, gene editing and genetic testing stocks.

        See the list below for genetics companies to consider, and check out the linked stock lists for more options.

        Large-cap gene stocks

        There are a number of large-cap biotech companies that have significant focuses on the field of genomics. Here are a few to consider:

        Amgen (NASDAQ:AMGN)
        A global leader in biotech, Amgen uses advanced human genetics to develop and manufacture therapeutics targeting a variety of diseases with unmet medical needs. The company’s subsidiary deCODE Genetics is researching how human genetic diversity influences disease.

        AbbVie (NYSE:ABBV)
        Research-based global biopharmaceutical company AbbVie that addresses several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology. AbbVie is collaborating with ADARx Pharmaceuticals to develop siRNA therapeutics, viewed as a promising genetic medicine approach for silencing disease-causing genes.

        Regeneron Pharmaceuticals (NASDAQ:REGN)
        Regeneron Pharmaceuticals creates medicines for a wide variety of diseases. The Regeneron Genetics Center is conducting one of the world’s largest genetics sequencing efforts in collaboration with health organizations around the world.

        Gene editing (CRISPR) stocks

        There are a variety of options for investors looking to buy in on the field of gene editing stocks, including:

        CRISPR Therapeutics (NASDAQ:CRSP)
        CRISPR Therapeutics and its partner Vertex Pharmaceuticals co-developed drug Casgevy, a CRISPR/Cas9 genome-edited cell therapy. Casgevy is the first ever treatment based on CRISPR technology to be approved for the US market, as well as by the European Medicines Agency and Health Canada.

        Intellia Therapeutics (NASDAQ:NTLA)
        Intellia Therapeutics is a gene editing biotech company developing drugs for patients with genetic and autoimmune diseases. The company’s drug pipeline includes late-stage clinical programs for therapies targeting hereditary angioedema and transthyretin amyloidosis.

        Vertex Pharmaceuticals (NASDAQ:VRTX)
        Vertex Pharmaceuticals is the other half of the team behind Casgevy. It also offers exposure to other sectors of genomics, with approved treatments for cystic fibrosis and a pipeline of genetic and cell therapies. Its investigational VX-880 islet cell replacement therapy could restore insulin production in patients with type 1 diabetes.

        Gene therapy stocks

        Gene therapy stocks and stem cell stocks are also popular choices for genetics investing. Here are a few to get you started:

        Novartis (NYSE:NVS)
        Switzerland-based Novartis is focused on treatments for a wide range of diseases, including cancers, malaria, leprosy and sickle cell disease. Novartis is developing adeno-associated-virus (AAV)-based and CRISPR-based gene therapies. Its Kymriah treatment was the first CAR-T cell therapy to be approved by the FDA, and the agency also approved its AAV-based therapy Zolgensma.

        Gilead Sciences (NASDAQ:GILD)
        Global biopharmaceutical company Gilead Sciences is advancing breakthrough medicines to prevent and treat serious diseases such as HIV, viral hepatitis and cancer. Its cell-based gene medicine for blood cancer, the CAR T-cell therapy Yescarta, was the second gene therapy approved by FDA.

        uniQure (NASDAQ:QURE)
        Genomic medicine company uniQure develops and markets gene therapy products for patients with severe genetic diseases. The company’s AAV-based gene therapy platform targets liver-directed and central nervous system disorders.

        Genetic testing stocks

        For those interested in genetic testing stocks, these three stocks provide a snapshot on different ways to get exposure to the sector:

        Exact Sciences (NASDAQ:EXAS)
        Exact Sciences focuses on molecular diagnostic tests. The company has developed a molecular screening technology platform called Cologuard that detects a range of cancers, including breast cancer and colorectal cancer.

        Fulgent Genetics (NASDAQ:FLGT)
        A leader in clinical diagnostic genetic sequencing, Fulgent Genetics is a full-service genomics testing company. Its proprietary technology platform, Picture Genetics, allows for the identification of personal DNA health markers in individual patients.

        Illumina (NASDAQ:ILMN)
        Illumina develops, manufactures and markets life science tools and integrated systems that enable the implementation of genomic solutions for the healthcare sector. Its focus is on oncology testing, genetic disease testing, reproductive health and research.

        How to invest in genomics ETFs

        For those who would prefer to invest in the genetics industry overall rather than buying shares in an individual gene stock, investing in genomics ETFs is the way to go. Here are some available ETFs that offer exposure to companies in the biotech and genetics sectors to start you off:

        ARK Genomic Revolution ETF (ARCA:ARKG)
        This ETF tracks firms focused on CRISPR technology, targeted therapeutics, bioinformatics, molecular diagnostics, stem cells and agricultural biology. Its holdings include CRISPR Therapeutics and Guardant Health (NASDAQ:GH).

        Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)
        The Global X Genomics & Biotechnology ETF invests in stocks that are involved in genomic science, which includes gene computational genomics and biotechnology. Its holdings include Illumina and Avidity Biosciences (NASDAQ:RNA).

        iShares Genomics Immunology and Healthcare ETF (ARCA:IDNA)
        The iShares Genomics Immunology and Healthcare ETF focuses on companies involved with genomics, immunology and bioengineering. Its holdings include Regeneron Pharmaceuticals and Arcellx (NASDAQ:ACLX).

        Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

        This post appeared first on investingnews.com